Published in Stroke Res Treat on November 10, 2011
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med (1995) 47.15
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2010) 6.93
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation (2006) 5.91
Inheritance and drug response. N Engl J Med (2003) 5.78
Genomics and drug response. N Engl J Med (2011) 4.35
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet (1997) 3.76
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (2007) 3.60
Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med (2009) 3.44
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol (2009) 2.64
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA (2001) 2.49
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J (2010) 2.46
Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke (2003) 2.32
Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample. Neurology (2006) 2.29
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol (2008) 2.12
A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res (2005) 2.05
A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet (2009) 1.78
Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res (2006) 1.78
Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res (2003) 1.44
A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med (Berl) (2000) 1.42
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics (2007) 1.40
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension. Am J Hypertens (2009) 1.40
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther (2008) 1.37
No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J Am Coll Cardiol (2011) 1.36
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA (2008) 1.30
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost (2010) 1.25
Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA (2002) 1.23
A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med (2005) 1.20
A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem (2001) 1.19
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics (2011) 1.12
Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke (2004) 1.09
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). Am Heart J (2008) 1.05
Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review. Glia (2005) 1.03
Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke (2004) 1.01
The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension (2003) 0.96
Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke (2006) 0.95
beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am J Hypertens (2008) 0.91
Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance. Pharmacogenomics (2009) 0.90
Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet (2007) 0.89
Genome response to tissue plasminogen activator in experimental ischemic stroke. BMC Genomics (2010) 0.89
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet Genomics (2010) 0.88
Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol (2001) 0.87
Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf (2011) 0.86
Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA. Eur J Hum Genet (2003) 0.83
Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thromb Haemost (2009) 0.82
Adducin polymorphisms and the treatment of hypertension. Pharmacogenomics (2007) 0.82
A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists. J Appl Genet (2009) 0.81
Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. Pharmacogenomics J (2008) 0.80
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenet Genomics (2008) 0.79
Editorial comment: Stroke and the CD40-CD40 ligand system: at the hinge between inflammation and thrombosis. Stroke (2003) 0.78
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenet Genomics (2009) 0.78
CD40-1C>T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke. Pharmacogenomics (2010) 0.78
The role of blood pressure lowering before and after stroke. Curr Opin Neurol (2003) 0.78
Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel. Curr Neurol Neurosci Rep (2011) 0.78
The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost (2008) 0.77
Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Thromb Haemost (2007) 0.77
ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neurosci Lett (2006) 0.77
Impact of genetic testing on complex diseases. Eur J Epidemiol (2005) 0.77
The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics (2002) 0.76
Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients. Cerebrovasc Dis (2009) 0.76
[ApoE genotype influences on efficacy and safety of thrombolytic treatment for ischemic stroke]. Neurologia (2006) 0.76
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med (2012) 10.64
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med (2002) 3.91
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg (2014) 3.43
Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation (2004) 2.69
Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke (2007) 2.60
Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation (2007) 2.54
Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J (2010) 2.52
Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med (2002) 2.16
Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol (2005) 2.14
Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol (2003) 2.13
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09
Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest (2006) 1.85
A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J (2004) 1.80
Anticoagulants in heart disease: current status and perspectives. Eur Heart J (2007) 1.73
Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res (2009) 1.72
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med (2012) 1.67
Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke (2008) 1.63
Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med (2006) 1.56
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med (2008) 1.54
Characteristics and outcomes of patients with multiple cervical artery dissection. Stroke (2013) 1.46
Combined oral anticoagulants and antiplatelets: benefits and risks. Intern Emerg Med (2010) 1.39
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J (2005) 1.39
A comparative analysis of the outcomes of carotid stenting and carotid endarterectomy in women. J Vasc Surg (2009) 1.38
Complications and functional outcomes after total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ) (2010) 1.25
Antiplatelets versus anticoagulation in cervical artery dissection. Stroke (2007) 1.25
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol (2005) 1.14
Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy. Cerebrovasc Dis (2007) 1.12
Cervical artery dissection: trauma and other potential mechanical trigger events. Neurology (2013) 1.12
Outcome in patients with stroke associated with internal carotid artery occlusion. Cerebrovasc Dis (2005) 1.12
Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments. Pharmacogenomics (2012) 1.11
Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost (2002) 1.09
What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? Thromb Res (2006) 1.08
The concept of ischemic penumbra in acute stroke and therapeutic opportunities. Eur Neurol (2009) 1.05
Dysphagia following Stroke. Eur Neurol (2004) 1.05
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica (2008) 1.00
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost (2012) 0.99
Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res (2012) 0.99
Hormone replacement therapy and stroke. Curr Vasc Pharmacol (2008) 0.99
The role of carotid artery stenting and carotid endarterectomy in cognitive performance: a systematic review. Stroke (2008) 0.99
Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. Cerebrovasc Dis (2010) 0.99
Prophylaxis against venous thromboembolism in patients with cancer. N Engl J Med (2014) 0.98
Validation of the DRAGON score in 12 stroke centers in anterior and posterior circulation. Stroke (2013) 0.98
Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature. Thromb Haemost (2010) 0.97
Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. Cerebrovasc Dis (2007) 0.97
Systemic thrombolysis in patients with acute ischemic stroke and Internal Carotid ARtery Occlusion: the ICARO study. Stroke (2011) 0.96
Gender differences in patients with acute ischemic stroke. Womens Health (Lond Engl) (2010) 0.95
96 hours ECG monitoring for patients with ischemic cryptogenic stroke or transient ischaemic attack. Intern Emerg Med (2012) 0.93
Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol (2007) 0.93
Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica (2007) 0.93
Association of vascular risk factors with cervical artery dissection and ischemic stroke in young adults. Circulation (2011) 0.92
Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J (2007) 0.92
The THRombolysis and STatins (THRaST) study. Neurology (2013) 0.92
Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest (2015) 0.92
Multidetector CT scan for acute pulmonary embolism: embolic burden and clinical outcome. Chest (2012) 0.91
Statins and stroke prevention. Cerebrovasc Dis (2007) 0.91
Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. Eur Urol (2006) 0.90
Clinical features and short term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). Thromb Res (2012) 0.90
Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. Cerebrovasc Dis (2009) 0.90
Admission leukocytosis in acute cerebral ischemia: influence on early outcome. J Stroke Cerebrovasc Dis (2011) 0.90
Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J (2011) 0.89
Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry. Thromb Res (2007) 0.89
Obesity and the risk of intracerebral hemorrhage: the multicenter study on cerebral hemorrhage in Italy. Stroke (2013) 0.89
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med (2011) 0.89